CTSO Upcoming Earnings (Q3 2023)
|Earnings Date:||Nov 01, 2023|
Current P/E* ratio: -3.20 | Price (Sep 29, 2023, EOD): $1.88
*The P/E ratio (price-to-earnings ratio) is a financial metric used to assess a company's stock valuation. It is calculated by dividing the stock price by its earnings per share. A higher ratio suggests higher investor expectations, while a lower ratio may indicate undervaluation. It helps investors evaluate potential investments, but it's essential to consider other factors too.
Last 2 Quarters for CTSO Premium
About Cytosorbents Corporation
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complication... CTSO Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.